Evidence map›Paper›PMID 38019094›Full record

ArticleAmerican journal of respiratory and critical care medicine2024

Ambient Ultrafine Particulate Matter and Clinical Outcomes in Fibrotic Interstitial Lung Disease.

Gillian C Goobie, Provat K Saha, Christopher Carlsten, Kevin F Gibson, Kerri A Johannson, Daniel J Kass, Christopher J Ryerson, Yingze Zhang, Allen L Robinson, Albert A Presto and 1 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Systematic review and meta-analysis on the health effects of long-term exposure to ultrafine particles.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Epigenome-Wide Analysis Identifies Pollution-Sensitive Loci in Fibrotic Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025
    Article
  5. Review
  6. Air pollution and alveolar health.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  7. Article
  8. Do Ultrafine Particles Carry Any Weight When It Comes to Progression of Pulmonary Fibrosis?American journal of respiratory and critical care medicine · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Gillian C GoobieCentre for Heart Lung Innovation and.ORCID 0000-0001-7982-5635
Provat K SahaCenter for Atmospheric Particle Studies and.ORCID 0000-0002-4044-9350
Christopher CarlstenCentre for Heart Lung Innovation and.
Kevin F GibsonDorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.
Kerri A JohannsonDivision of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-1205-5511
Daniel J KassDorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.ORCID 0000-0001-6597-7830
Christopher J RyersonCentre for Heart Lung Innovation and.
Yingze ZhangDorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.ORCID 0000-0001-6947-2901
Allen L RobinsonCenter for Atmospheric Particle Studies and.
Albert A PrestoCenter for Atmospheric Particle Studies and.
S Mehdi NouraieDorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.ORCID 0000-0001-7465-0581
University of Pittsburgh · USCarnegie Mellon University · USUniversity of British Columbia · CABangladesh University of Engineering and Technology · BDUniversity of Calgary · CAVancouver Coastal Health · CA

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesisP50AR060780 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2011 to 2021
$14.9M
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary FibrosisU01HL133232 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CRINER, GERARD J, DUNCAN, STEVEN R · 2017 to 2021
$3.8M
A novel approach to reverse the ineffectiveness of relaxin-based anti-fibrotic therapy in SScR21AR076024 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, YINGZE · 2019 to 2020
$379k
NCATS NIH HHS UL1 TR001857NHLBI NIH HHS U01 HL133232NIAMS NIH HHS P50 AR060780NIAMS NIH HHS R21 AR076024Pulmonary Fibrosis Foundation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lung Diseases, InterstitialParticulate MatterAgedCohort StudiesEnvironmental ExposureFemaleHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesParticulate Matterair pollutionidiopathic pulmonary fibrosisILDparticulate matter with an aerodynamic diameter ⩽2.5 μmultrafine particulate matter

Identifiers

PMID38019094
PMCPMC11092946
OpenAlexW4389136978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.